Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc > Q1 highlights
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1998)
•••
Comment by lscfaon May 11, 2020 2:26pm
195 Views
Post# 31013185

RE:Q1 highlights

RE:Q1 highlights Good cash flow after interest on debt (cfo)....

 

 

Revenue

Adj. revenue

Cfo 

Adj ebitda 

Q1 20

24,361

18,913

6,203

7,990

Q4 19

19,593

19,644

6,987

8,570

Q3 19

18,823

18,889

6,603

7,784

Q2 19 

16,580

19,708

1,457

5,663

Q1 19

14,550

17,112

1,385

5,224

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities